Literature DB >> 2989562

Truncated gag-related proteins are produced by large deletion mutants of Rous sarcoma virus and form virus particles.

S L Voynow, J M Coffin.   

Abstract

Large deletion (LD) mutants of Prague strain Rous sarcoma virus subgroup B (PrB), derived by serial undiluted passage through chicken (C/E) cells, contain two deletions relative to wild-type virus. One of these joins gag sequences in the p12 coding region to env sequences in region encoding gp37; the other deletion spans the src region. Analysis of the viral proteins of QT6 cell clones containing only LD proviruses by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a major truncated gag-related phosphoprotein of 60,000 to 66,000 daltons (P63LD). P63LD was stable, but could be cleaved in vitro to the predicted products by p15gag. A second gag-related LD protein of about 68,000 to 74,000 molecular weight (P70LD) was also found which often reacted with an anti-gp37 serum. P70LD was unstable and may represent a short-lived gag-gp37 fusion protein. Finally, immunoprecipitation indicated that particles containing P63LD were shed from QT6-LD clones. Thin section preparations of these clones viewed in an electron microscope showed enveloped budding particles of "immature" morphology. Thus, the synthesis and release of particles from infected cells does not require cleavage of the gag precursor, nor does it require the presence of p15 or (most of) p12.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2989562      PMCID: PMC254900     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Electron microscope studies of tumor virus RNA.

Authors:  H J Kung; J M Bailey; N Davidson; P K Vogt; M O Nicolson; R M McAllister
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1975

2.  The genome-associated, specific RNA binding proteins of avian and mammalian type C viruses.

Authors:  A Sen; G J Todaro
Journal:  Cell       Date:  1977-01       Impact factor: 41.582

3.  Properties of a ribonucleoprotein particle isolated from Nonidet P-40-treated Rous sarcoma virus.

Authors:  N L Davis; R R Rueckert
Journal:  J Virol       Date:  1972-11       Impact factor: 5.103

4.  Localization of RNA tumor virus polypeptides. I. Isolation of further virus substructures.

Authors:  D P Bolognesi; R Luftig; J H Shaper
Journal:  Virology       Date:  1973-12       Impact factor: 3.616

5.  Properties of mouse leukemia viruses. 3. Electron microscopic appearance as revealed after conventional preparation techniques as well as freeze-drying and freeze-etching.

Authors:  M V Nermut; H Frank; W Schäfer
Journal:  Virology       Date:  1972-08       Impact factor: 3.616

6.  Formation of an infectious virus-antibody complex with Rous sarcoma virus and antibodies directed against the major virus glycoprotein.

Authors:  M J Schlesinger
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

7.  Continuous tissue culture cell lines derived from chemically induced tumors of Japanese quail.

Authors:  C Moscovici; M G Moscovici; H Jimenez; M M Lai; M J Hayman; P K Vogt
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

8.  Surface-active agents for isolation of the core component of avian myeloblastosis virus.

Authors:  K Stromberg
Journal:  J Virol       Date:  1972-04       Impact factor: 5.103

9.  Structural studies of avian myeloblastosis virus: comparison of polypeptides in virion and core component by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Stromberg; N E Hurley; N L Davis; R R Rueckert; E Fleissner
Journal:  J Virol       Date:  1974-02       Impact factor: 5.103

10.  Role of methylation in the induced and spontaneous expression of the avian endogenous virus ev-1: DNA structure and gene products.

Authors:  K F Conklin; J M Coffin; H L Robinson; M Groudine; R Eisenman
Journal:  Mol Cell Biol       Date:  1982-06       Impact factor: 4.272

View more
  21 in total

1.  Transposition of a Ty3 GAG3-POL3 fusion mutant is limited by availability of capsid protein.

Authors:  J Kirchner; S B Sandmeyer; D B Forrest
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  Protein delivery using engineered virus-like particles.

Authors:  Stanislaw J Kaczmarczyk; Kalavathy Sitaraman; Howard A Young; Stephen H Hughes; Deb K Chatterjee
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

3.  Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly.

Authors:  S S Rhee; E Hunter
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

4.  Mechanical properties of murine leukemia virus particles: effect of maturation.

Authors:  Nitzan Kol; Micha Gladnikoff; David Barlam; Roni Z Shneck; Alan Rein; Itay Rousso
Journal:  Biophys J       Date:  2006-04-21       Impact factor: 4.033

5.  Properties of avian retrovirus particles defective in viral protease.

Authors:  L Stewart; G Schatz; V M Vogt
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

6.  Role of the gag polyprotein precursor in packaging and maturation of Rous sarcoma virus genomic RNA.

Authors:  S Oertle; P F Spahr
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

7.  Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly.

Authors:  R C Craven; R P Bennett; J W Wills
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

8.  Rous sarcoma virus nucleic acid-binding protein p12 is necessary for viral 70S RNA dimer formation and packaging.

Authors:  C Méric; P F Spahr
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

9.  Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells.

Authors:  J W Wills; R C Craven; J A Achacoso
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

10.  Design requirements for interfering particles to maintain coadaptive stability with HIV-1.

Authors:  Igor M Rouzine; Leor S Weinberger
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.